Skip to content
Markets

Bristol Myers reports early Cobenfy data for Alzheimer’s-related psychosis

Bristol Myers Squibb reported lower symptom scores in patients who knew they were receiving the drug. Blinded results will help show how it compares with a placebo.

By Alex Morgan2 min read

Alex Morgan is an editorial pen name used for AI-assisted news summaries by tailorinvests.com.

Illustration of a translucent blue brain model, an unmarked capsule and a blank lab notebook.
AI-generated editorial illustration

Bristol Myers Squibb said on November 18 that clinician ratings of hallucinations and delusions improved among people taking its drug KarXT in two preliminary Phase 3 analyses for psychosis associated with Alzheimer’s disease. The company announced the findings at 9:10 a.m. Eastern time and presented them at a clinical trials conference in Boston. Patients and researchers knew what treatment was being given in both groups discussed in the update.

The same drug is sold as Cobenfy in the United States for adults with schizophrenia. The studies are testing a different use: managing psychosis in people with Alzheimer’s disease. The findings don’t answer whether it slows Alzheimer’s itself.

What the studies measured

In the first 12 weeks of ADEPT-1, clinicians tracked changes in hallucinations and delusions after participants began taking the drug. Bristol Myers reported that the average score fell by 12 points from a starting average of 14.4 among 266 participants with those measurements. A lower score indicates less severe symptoms on that scale.

The 52-week extension, ADEPT-3, was designed to give researchers a longer view of how patients tolerate the drug. The company reported that 7.7% of participants experienced serious adverse events that began or worsened during treatment. That count does not establish that the drug caused those events. The analyses excluded participants still in the respective treatment periods at the cutoff.

What would make the evidence stronger

Symptoms can change over time for several reasons, and knowing which treatment someone receives can influence how changes are reported or rated. In the blinded part of ADEPT-1, eligible participants are randomly assigned to continue treatment or switch to a placebo. That comparison is designed to show whether continuing the drug reduces the risk of symptoms returning.

For investors, a drug with one approved use can grow if it earns approval for another. The milestone to watch here is the blinded evidence on how well the treatment works and how patients tolerate it. The preliminary findings leave the prospects for a broader approval and any future sales uncertain.

Go to the source

For general education. Consider your circumstances and local rules before making investment decisions. Figures describe the dates stated in this article and are not live market quotes.

Build your investing knowledge